Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation

Premature Ejaculation Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00983151
• Other study ID #: BVF-324-301
• Status: Terminated
• Phase: Phase 3
• First received: September 22, 2009
• Last updated: August 24, 2012
• Start date: August 2009
• Est. completion date: September 2010

Study information

• Verified date: October 2010
• Source: Valeant Pharmaceuticals International, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Federal Office for Safety in Health CareBelgium: Federal Agency for Medicinal Products and Health ProductsFrance: Ministry of HealthGermany: Ministry of HealthItaly: Ethics CommitteeNetherlands: Independent Ethics CommitteeSpain: Ethics CommitteeSweden: Regional Ethical Review BoardUnited Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to test an experimental drug therapy called Tramadol Hydrochloride (HCl) Orally Disintegrating Tablets (ODT) ("Tramadol HCl ODT" or the "study drug"). The subject and his partner are being asked to be in this clinical trial because they have a condition called premature ejaculation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1050
• Est. completion date: September 2010
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Subjects are eligible for study participation if all of the following criteria are met:

1. Male subject and female partner to provide written informed consent prior to the performance of any study-specific procedures;

2. Candidates will be male subjects aged 18-65 years inclusive, with lifelong premature ejaculation ("lifelong" is defined as starting at the time the subject became sexually active) with an IELT of =120 seconds as documented at Visit 2.

3. History of premature or rapid ejaculation, determined by following criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV TR):

1. Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after vaginal insertion and before the person wishes it, taking into account factors that affect duration of the excitement phase such as age, novelty of the sexual partner or situation and recent frequency of sexual activity

2. The disturbance causes marked distress or interpersonal difficulty

3. The premature ejaculation is not due exclusively to the direct effects of a substance (ab)use

4. In a stable, monogamous, heterosexual relationship (> 6 months).

5. Willing and able to take study medication as directed at least 2 hours prior to sexual intercourse according to protocol;

6. Subject willing and able to complete the therapeutic trial, all sexual behavior logs, IELT assessments, questionnaires and interviews:

7. Female sexual partner willing and able to complete the therapeutic trial, all sexual behavior logs, IELT assessments, questionnaires and interviews;

8. Able to understand the study procedures, complete the assessments, and communicate with study personnel;

9. Subject and partner willing and able to engage in vaginal intercourse at least three times between visits to yield at least three events of vaginal intercourse ;

10. Subject and partner willing to use a reliable contraceptive method during the trial period if the partner is not menopausal;

11. Partner willing to take pregnancy tests at Visits 1 and 2

12. Subject willing to list and document prescription and non-prescription drug use during the study;

13. Have a negative urine drug screen at Visits 1 and 2;

14. Be in good general health as determined by medical history and physical examination and expected by the Investigator to complete the study as designed.

Exclusion Criteria:

Subjects are not eligible for study participation if any of the following criteria are met:

1. Premature ejaculation attributable to situational or relationship issues;

2. Evidence or a history of other significant psychiatric disorder as defined as requiring therapy or medication;

3. Subjects who in the Investigator's opinion are at significant risk of suicide.

4. Physical illnesses i.History of seizures ii.Prostatitis (current) iii.Urethritis or other urinary tract infections (current) iv.Prior genital surgery (other than vasectomy or circumcision) v.Uncontrolled Diabetes mellitus vi.Respiratory Depression vii.Thyroid disease viii.Chronic moderate to severe neurological disease ix.Significant heart disease treated with cardiac drugs x.Chronic liver disease xi.Chronic kidney disease xii.History of cardiovascular disease (myocardial infarction, congestive heart failure, angina, coronary artery disease or stroke) xiii.Known to be a carrier of the hepatitis B surface antigen, hepatitis C virus antibody, and/or immunodeficiency virus-1 and/ or 2 antibodies xiv.Other disorder that may cause sexual dysfunction

5. Other sexual dysfunction:

i.Erectile dysfunction. As defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV TR), the diagnostic criteria for male erectile disorder (302,72) erectile dysfunction includes:

A.Persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate erection.

B.The disturbance causes marked distress or interpersonal difficulty. ii.Primary reduced sexual desire unrelated to premature ejaculation

6. Sexual intercourse usually less than once per week;

7. Partner sexual dysfunction (for example dyspareunia or other conditions considered relevant);

8. Current use of dapoxetine;

9. Current use of any tramadol;

10. Sensitivity to phenylketone;

11. Any history of abuse of prescription opioids and/or illicit/illegal addictive drugs;

12. Has a known hypersensitivity to heparin or history of heparin induced thrombocytopenia;

13. Use of medication, within the preceding 30 days, with potential to cause sexual dysfunction: (See Appendix 2 for a list of excluded medications) i.Antidepressants - all types

ii.Antipsychotic medication

iii.Antihypertensive medication, unless on a stable dose > 6 months

iv.Hormonal drugs

v.Chemotherapy

vi.Others: cimetidine, clofibrate,quinidine

14. Recent psychotropic drug use (within the past 30 days);

15. A history of alcohol abuse or dependence within the past 6 months as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV TR);

16. Initiation of psychosexual counseling during the screening, baseline or treatment periods;

17. Partner positive pregnancy test at Visit 1 or 2;

18. History of clinically significant intolerance or a known hypersensitivity to tramadol, such that treatment with it is contraindicated;

19. The Investigator anticipates that the subject will be unable to comply with the protocol;

20. Received any investigational drug within 30 days prior to Visit 1 or is scheduled to receive an investigational drug during the course of this study;

21. Has preplanned surgery or procedures that would interfere with the course of the study.

22. A family member (other than the female partner), a staff member, or relative of a staff member..

23. Significant laboratory abnormality as determined by the Investigator at Visit 1;

24. Significant ECG abnormality at Visit 1 as determined by the Investigator;

25. Any other illnesses, conditions or practices that in the Investigator's opinion could interfere with the collection and/or interpretation of study results (couples using the "Withdrawal Method" of birth control will be excluded from the study).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Premature Birth
• Premature Ejaculation

Intervention

Drug:
• Tramadol Hydrochloride & Placebo
89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks

Locations

Country	Name	City	State
Austria	Innsbruck Medical university	Innsbruck
Belgium	Ziekenhuisnelwerk Antwerpen (ZNA), Campus Stuvenberg-St. Erasmus	Antwerpen
Belgium	UZ Brussel, Laarbeeklaan 101	Brussel
Belgium	Clinique St. Jean, Depart. of Urology, Blvd du Jardin Botanique, 32	Bruxelles
Belgium	Universitair Ziekenhuls Antwerpen (UZA), Wirjkstraat 10	Edegem
Belgium	Universitair Ziekenhuis Gent	Gent
Belgium	CHU Sart Tilman	Liege
France	CHU de Nimes-Groupe Hospitalo-Universitaire, Pharmacie Secteur Essals Cliniques,	Cedex
France	Hopital Raymond Poincar'e, 104 Bvld. Raymond Poincar'e	Garches
France	Hopital Henry Gabrielle	Laval
France	Porle Bouqueyre	Le Parc Saint Maur
France	CETPARPjj	Lille
France	hopital Edouard Herriot	Lyon
France	Institut de Medecine Sexuelle	Marseille
France	Hopital Pasteur	Nice
France	11 rue Magellan	Paris
France	Cabinet medical	Paris
France	76 rue d'Antain, 35700 Rennes	Rennes
France	Cabinet medical, 10 rue de la Trinite	Toulouse
Germany	Dederweg 2-4	Frankfurt
Germany	University Hospital Halle	Halle
Germany	Institut fur Mannergesundheit Universitakslinikum Hamburg-Eppendorf	Hamburg
Germany	Medizinische Hochschule Hannover Zentrum for Seelische Gesundhelt	Hannover
Germany	Abetellung for Andrologie & Urologie PAN-Kilnik am Neumarkt	Koin
Germany	PUR/R Praxisklinik Urologie 3 Rhein Ruhr	Muhlheim
Netherlands	Academic Medical Center, Depart. of Urology	Amsterdam
Netherlands	Geert Grooteplein Zuid	Nijmegen
Spain	Hospital Universitario Reina Sofla	Cordoba
Spain	Hospital Universitario Fundacion Alcordon	Madrid
Spain	Clinica El Angel	Malaga
Spain	Hospital Universitario Virgen de Rocio	Sevilla
Sweden	DW Medical	Eskilstuna
Sweden	Carlanderska Sjukhuset	Goteborg
Sweden	Urohalsan	Jonkoping
Sweden	ProbarE AB	Lund
Sweden	ProbarE AB	Solna
Sweden	Karolinska University hospital-Huddinge	Stockholm
Sweden	S3 Clinical Research Centers	Vällingby

Sponsors (1)

Lead Sponsor	Collaborator
Valeant Pharmaceuticals International, Inc.

Countries where clinical trial is conducted

Austria,  Belgium,  France,  Germany,  Netherlands,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Increase in IELT (Intravaginal ejaculatory time)		Per attempt at sexual intercourse	No
Secondary	Efficacy of using Tramadol for Premature Ejaculation.		At each attempt	No